Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neelima Denduluri

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri, Jennifer A Low, James J Lee, et al.
Nature Cancer|June 8, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trialPeter Schmid, Seock-Ah Im, Zbigniew Nowecki, et al.
Clinical Breast Cancer|September 19, 2019
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence ScoreNicole Casasanta, Sarit T Kipnis, Laura Linville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox, Jennifer Low, James Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice GuidelineNeelima Denduluri, Mark R Somerfield, Andrea Eisen, et al.
Journal of Genetic Counseling|October 3, 2020
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE studyFilipa Lynce, Ilana Schlam, Xue Geng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesNeelima Denduluri, Debra A Patt, Yunfei Wang, et al.
Seminars in Oncology|December 17, 2013
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Jeanne S Mandelblatt, Arti Hurria, Brenna C McDonald, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Innovations in American Society of Clinical Oncology Practice Guideline DevelopmentMark R Somerfield, Kari Bohlke, George P Browman, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri, Jennifer A Low, James J Lee, et al.
Nature Cancer|June 8, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trialPeter Schmid, Seock-Ah Im, Zbigniew Nowecki, et al.
Clinical Breast Cancer|September 19, 2019
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence ScoreNicole Casasanta, Sarit T Kipnis, Laura Linville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox, Jennifer Low, James Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice GuidelineNeelima Denduluri, Mark R Somerfield, Andrea Eisen, et al.
Journal of Genetic Counseling|October 3, 2020
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE studyFilipa Lynce, Ilana Schlam, Xue Geng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesNeelima Denduluri, Debra A Patt, Yunfei Wang, et al.
Seminars in Oncology|December 17, 2013
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Jeanne S Mandelblatt, Arti Hurria, Brenna C McDonald, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Innovations in American Society of Clinical Oncology Practice Guideline DevelopmentMark R Somerfield, Kari Bohlke, George P Browman, et al.
Pageof 6